Using mobile health to manage atrial fibrillation and reduce unnecessary cardioversion procedures
The Effect of Integrated Mobile Health-supported Heart Rhythm Management Around Electrical Cardioversion in Terms of Cancelling Unnecessary Scheduled ECV Appointments in Patients With Presumed Persistent Atrial Fibrillation (TeleConvert-AF)
This study is testing a mobile app that helps people with atrial fibrillation track their heart activity to see if it can reduce unnecessary heart procedures.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 264 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Maastricht University Medical Center Academic / other |
| Locations | 2 sites (Maastricht, Limburg and 1 other locations) |
| Trial ID | NCT06359132 on ClinicalTrials.gov |
What this trial studies
This observational study aims to improve the management of patients with presumed persistent atrial fibrillation (AF) who are scheduled for electrical cardioversion (ECV). By utilizing a mobile health (mHealth) app that monitors heart rate and rhythm, the study seeks to differentiate between paroxysmal and persistent AF more effectively. Patients will use the app to record their heart activity, and alerts will notify their care team of any concerning changes. This approach aims to reduce unnecessary hospital visits and interventions by confirming sinus rhythm before ECV is performed.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older with presumed persistent atrial fibrillation who are scheduled for electrical cardioversion and possess a smartphone.
Not a fit: Patients who have an active implanted electronic cardiac device or are deemed unsuitable for participation by their physician may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to fewer unnecessary cardioversion procedures and reduced healthcare costs for patients and hospitals.
How similar studies have performed: Other studies utilizing mobile health technologies for cardiac monitoring have shown promise, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Presumed persistent AF * Scheduled for ECV * Age ≥18 years * Smartphone possession * Ability and willing to sign informed consent * Ability and willing to use mobile phone app (FibriCheck) Exclusion Criteria: * Deemed unsuitable for participation by attending physician * Presence of an active implanted electronic cardiac device
Where this trial is running
Maastricht, Limburg and 1 other locations
- Maastricht University Medical Center — Maastricht, Limburg, Netherlands (Recruiting)
- Viecuri Medical Center — Venlo, Limburg, Netherlands (Recruiting)
Study contacts
- Study coordinator: Dominik Linz, dr.
- Email: dominik.linz@mumc.nl
- Phone: 043-3877098
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.